连亏股华神科技拟不超4.5亿定增 预计去年亏超前三季

Core Viewpoint - Huasheng Technology (000790.SZ) plans to issue A-shares to a specific entity, Yuanhong Biology, which is an indirect controlling shareholder, constituting a related party transaction. The shares will be subscribed for in cash [1][2]. Group 1: Share Issuance Details - The number of shares to be issued is up to 142,857,142 at a price of 3.15 yuan per share, which is not less than 80% of the average trading price over the last 20 trading days [2]. - The total amount raised from this issuance will not exceed 45 million yuan, and the net proceeds will be used entirely for replenishing working capital and repaying loans [2][3]. - After the issuance, Yuanhong Biology will hold 18.64% of the total shares, while the actual controllers, Huang Mingliang and Ouyang Ping, will maintain control of 33.17% of the company [3]. Group 2: Financial Performance Overview - For the year 2025, the company anticipates a net loss attributed to shareholders, influenced by strategic adjustments, price reductions of core products, and asset impairments [4]. - In the third quarter of 2025, the company reported revenue of 166.7 million yuan, a decrease of 19.26% year-on-year, with a net loss of approximately 42.94 million yuan [5]. - For the year 2024, the company achieved revenue of 864 million yuan, down 13.89% from 2023, with a net loss of approximately 6.69 million yuan [6].